HCW Biologics Inc is trading at $1.37 (5.5% down) after investors reacted to a resale registration for up to 5.7 million shares tied to a recent private placement.

  • The filing enables selling stockholders to resell these shares, adding perceived overhang and dilution risk to the stock.
  • Shares remain under pressure despite a broadly firmer backdrop in the U.S. equity markets.